BIIB — BIOGEN INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on BIIB
| date | signal | measured base rate |
|---|---|---|
| 2026-08-19 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-08-19 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-07-09 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-29 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-26 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-06-25 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-04 | Minor Lloyd Director | Open-market sale 10b5-1 plan | 593 | 200.96 | 119.2K |
| 2026-08-03 | Minor Lloyd Director | Open-market sale 10b5-1 plan | 593 | 203.34 | 120.6K |
| 2026-06-09 | Pangalos Menelas N Director | Grant or award | 1.5K | 0.00 | 0 |
| 2026-06-09 | Pangalos Menelas N Director | Option exercise | 2.4K | 0.00 | 0 |
| 2026-06-09 | LANGER SUSAN Director | Grant or award | 1.5K | 0.00 | 0 |
| 2026-06-09 | Patolawala Monish D Director | Grant or award | 1.5K | 0.00 | 0 |
| 2026-06-09 | Minor Lloyd Director | Grant or award | 1.5K | 0.00 | 0 |
| 2026-06-09 | Mantas Jesus B Director | Grant or award | 1.5K | 0.00 | 0 |
| 2026-06-09 | Rowinsky Eric K Director | Grant or award | 1.5K | 0.00 | 0 |
| 2026-06-09 | Freire Maria C Director | Grant or award | 2.0K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 2.9B | 16.0M |
| PRIMECAP MANAGEMENT CO/CA/ | 2.7B | 14.8M |
| FMR LLC | 2.3B | 12.8M |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7B | 9.5M |
| STATE STREET CORP | 1.3B | 7.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.2B | 6.5M |
| GEODE CAPITAL MANAGEMENT, LLC | 793.4M | 4.3M |
| WELLINGTON MANAGEMENT GROUP LLP | 543.0M | 3.0M |
| MORGAN STANLEY | 398.0M | 2.2M |
| JPMORGAN CHASE & CO | 378.1M | 2.0M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- How Investors Are Reacting To Biogen (BIIB) Raising EPS Guidance On Late-Stage Drug Trial Milestones - Sahm · 2026-08-23 · Sahm
- How Investors Are Reacting To Biogen (BIIB) Raising EPS Guidance On Late-Stage Drug Trial Milestones - simplywall.st · 2026-08-22 · simplywall.st
- What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders - Yahoo! Finance Canada · 2026-08-21 · Yahoo! Finance Canada
- Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month? - TradingView · 2026-08-20 · TradingView
- Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation · 2026-08-13
Ask the AI about BIIB
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →